| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/27/2007 | US20070298092 Compositions for Delivery of Drug Combinations |
| 12/27/2007 | US20070298091 Transdermal Therapeutic System For Administering Analgesics |
| 12/27/2007 | US20070298090 Intraoral delivery of nicotine for smoking cessation |
| 12/27/2007 | US20070298088 Tooth Whitening products |
| 12/27/2007 | US20070298087 Two-phase mucoadhesive composition |
| 12/27/2007 | US20070298086 Tussi bag |
| 12/27/2007 | US20070298085 Skin Sanitizing Object |
| 12/27/2007 | US20070298084 Flat System for Using in the Oral Cavity |
| 12/27/2007 | US20070298081 Alleviating acute alcohol intoxication/side effects of a hangover by administering, for example, 2,3-dimercapto-1-propanol; food additives/supplements; animal feed; oxidation resistance; immunostimulants; demetallization; shelf life cosmetology; dermatology; food additives/supplements; feeds; drugs |
| 12/27/2007 | US20070298078 Water Soluble Article for Imparting Dietary Fiber to Bottled Water |
| 12/27/2007 | US20070298076 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/27/2007 | US20070298066 Biodegradable linkers for molecular therapies |
| 12/27/2007 | US20070298065 2-Cyclopentyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide; amidation; oxidation; cyclization; |
| 12/27/2007 | US20070298061 Process for manufacturing a delivery system for active components as part of an edible compostion |
| 12/27/2007 | US20070298060 Method for depletion of caries-causing bacteria in the oral cavity |
| 12/27/2007 | US20070298058 Pharmaceutical compositions comprising ascomycin |
| 12/27/2007 | US20070298057 Composition and method for modulating addictive behaviors |
| 12/27/2007 | US20070298056 Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| 12/27/2007 | US20070297991 Neural conduit agent dissemination for smoking cessation and other applications |
| 12/27/2007 | US20070297989 Novel anti-inflammatory androstane derivatives |
| 12/27/2007 | US20070297988 Optical probes for in vivo imaging |
| 12/27/2007 | US20070297987 Anti-Adhesion Sheet |
| 12/27/2007 | US20070296099 Systems for producing multilayered particles, fibers and sprays and methods for administering the same |
| 12/27/2007 | DE4240430B4 Stabilisiertes pharmazeutisches Mittel, enthaltend einen HMG-CoA-Reduktase-Inhibitor Wirkstoff A stabilized pharmaceutical composition comprising an HMG-CoA reductase inhibitor active agent |
| 12/27/2007 | DE102006028916A1 Production of silicon porous particles for the application of active substances, comprises doping an area of a silicon wafer, producing recesses in the silicon wafer, porosifying of the silicon wafer, and removing of the porous particles |
| 12/27/2007 | DE102006028915A1 Preparing porous silicon hollow body, used in producing dosage unit to treat e.g. pain, comprises passivating and masking the surface of silicon body, anisotropic etching, porosifying the canal of silicon and electro polishing |
| 12/27/2007 | DE102006028783A1 Porous silicon body with layered structure, useful for producing a drug delivery unit for treating e.g. pain, comprises a first outer layer, an intermediate layer and a second outer layer in that pore channels are perpendicularly arranged |
| 12/27/2007 | DE102006028780A1 Producing porous silicon body with lens-shaped structure comprises applying the lens-like photolacquer coat, transferring the coat shape to the silicon surface by etching, masking silicon surface and porosing the non-masked silicon surface |
| 12/27/2007 | DE10033990B4 Nanopartikel aus einem substituierten Cyclodextrin, dessen Verwendung und diese enthaltenden Zubereitungen Nanoparticles consisting of a substituted cyclodextrin, its use and these preparations containing |
| 12/27/2007 | CA2666688A1 Reduced coenzyme q10-containing composition and method for producing the same |
| 12/27/2007 | CA2660650A1 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| 12/27/2007 | CA2660649A1 Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| 12/27/2007 | CA2658337A1 Anti-inflammatory dissolvable film |
| 12/27/2007 | CA2657437A1 Segmented pharmaceutical dosage forms |
| 12/27/2007 | CA2655843A1 Punctal plugs for the delivery of active agents |
| 12/27/2007 | CA2655835A1 Abuse-resistant pharmaceutical compositions of opioid agonists |
| 12/27/2007 | CA2655802A1 Punctal plugs for the delivery of active agents |
| 12/27/2007 | CA2655296A1 Methods of using a thiazole derivative |
| 12/27/2007 | CA2655044A1 Encapsulated labile compound compositions and methods of making the same |
| 12/27/2007 | CA2654872A1 Galenical formulations of aliskiren and hydrochlorothiazide |
| 12/27/2007 | CA2654663A1 Enteric coated particles containing an active ingredient |
| 12/27/2007 | CA2654510A1 Vegf antagonist formulations suitable for intravitreal administration |
| 12/27/2007 | CA2654493A1 Tablets comprising candesartan cilexetil |
| 12/27/2007 | CA2654408A1 Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance |
| 12/27/2007 | CA2654243A1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 12/27/2007 | CA2654115A1 Aqueous suspensions of tmc278 |
| 12/27/2007 | CA2654113A1 Sustained release formulations of aromatase inhibitors |
| 12/27/2007 | CA2649121A1 High performance reticulated elastomeric matrix |
| 12/27/2007 | CA2648993A1 Grafted polymers and uses thereof |
| 12/27/2007 | CA2637036A1 Water stabilized aerosol formulation system and method of making |
| 12/27/2007 | CA2635314A1 Steroid-containing sustained release intraocular implants and related methods |
| 12/26/2007 | EP1870650A1 Lyophilisation targeting defined residual moisture by limited desorption energy levels |
| 12/26/2007 | EP1870649A1 Lyophilisation targetting defined residual moisture by limited desorption energy levels |
| 12/26/2007 | EP1870122A2 Metered dose inhaler |
| 12/26/2007 | EP1870110A1 Preparation comprising microparticles of complex composed of nucleic acid molecule and collagen |
| 12/26/2007 | EP1870108A1 Antitumor agent and novel dnase |
| 12/26/2007 | EP1870105A1 Use of fucans in the treatment of psoriasis |
| 12/26/2007 | EP1870102A1 Solid forms containing meloxicam with improved taste and process for their preparation |
| 12/26/2007 | EP1870101A1 Aerosol formulation for inhalation containing an anticholinergic agent |
| 12/26/2007 | EP1870100A1 Pharmaceutical composition for oral application comprising ethyl 3-(2-(4-(hexyloxycarbonylamidino)phenylaminomethyl)-1-methyl-1H-benzimidazole-5-carbonyl)-2-pyridylamino)propionate mesylate |
| 12/26/2007 | EP1870092A2 Ocular implant made by a double extrusion process |
| 12/26/2007 | EP1870091A1 Liposome composition for induction of immunity |
| 12/26/2007 | EP1870090A2 Novel stable formulation of suspended aerosols and production method thereof |
| 12/26/2007 | EP1870089A1 A gynecological pharmaceutics-containing microspherical vascular suppository of sodium alginate and its preparation method |
| 12/26/2007 | EP1869092A1 Hydrophilic core polymeric micelles for the delivery of water-soluble compounds |
| 12/26/2007 | EP1868686A2 Antimicrobial pet wipes |
| 12/26/2007 | EP1868661A1 Sustained release implants for subretinal delivery |
| 12/26/2007 | EP1868620A1 Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| 12/26/2007 | EP1868610A2 Biocompatible polymer compounds for medicinal formulations |
| 12/26/2007 | EP1868590A2 Method of increasing testosterone and related steroid concentrations in women |
| 12/26/2007 | EP1868589A1 A process for the preparation of poly dl-lactide-co-glycolide nanoparticles having antitubercular drugs encapsulated therein |
| 12/26/2007 | EP1868588A2 Capsules containing seminal material for artificial insemination |
| 12/26/2007 | EP1868587A2 Pharmaceutical formulations comprising fenofibric acid and/or its salts |
| 12/26/2007 | EP1868586A1 Anti-inflammatory formulation |
| 12/26/2007 | EP1868585A2 Abuse resistant capsules |
| 12/26/2007 | EP1868584A1 Dosage forms of risedronate |
| 12/26/2007 | EP1868583A1 Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
| 12/26/2007 | EP1868582A1 Nanoparticulate and controlled release compositions comprising cyclosporine |
| 12/26/2007 | EP1868581A1 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
| 12/26/2007 | EP1868580A1 Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance |
| 12/26/2007 | EP1868579A1 Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
| 12/26/2007 | EP1868578A2 Nanoparticulate corticosteroid and antihistamine formulations |
| 12/26/2007 | EP1868577A1 Lacidipine particles |
| 12/26/2007 | EP1868576A2 Injectable compositions of nanoparticulate immunosuppressive compounds |
| 12/26/2007 | EP1868575A1 Cosmetic compositions, methods of applying said compositions, and methods of making said compositions |
| 12/26/2007 | EP1868574A2 Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof |
| 12/26/2007 | EP1868573A2 Method for producing ultrafine submicronic suspensions |
| 12/26/2007 | EP1868572A2 Administration of glutathione (reduced) via intravenous or encapsulated in liposome for treatment of tnf-alpha effects and elu-like viral symptoms |
| 12/26/2007 | EP1868571A1 Mitochondriotropic phospholipid vesicles |
| 12/26/2007 | EP1868570A2 Methods and systems for operating an aerosol generator |
| 12/26/2007 | EP1868569A1 Liquid aqueous dosage forms for sub-lingual or nasal applications of active agents with amino groups |
| 12/26/2007 | EP1868567A1 Compositions with hydrophilic drugs in a hydrophobic medium |
| 12/26/2007 | EP1868566A2 Controlled release devices and structural elements for use in their manufacture |
| 12/26/2007 | EP1868448A2 Methods and compositions for modified release of nutritional supplements |
| 12/26/2007 | EP1868437A1 Method of treating or preventing bone deterioration or osteoporosis |
| 12/26/2007 | EP1778193B1 Sustained release pharmaceutical particulate composition comprising venlafaxine |
| 12/26/2007 | EP1750688B1 Steroid intraocular implants having an extended sustained release for a period of greater than 2 months |
| 12/26/2007 | EP1691744A4 Methods and reagents for the treatment of inflammatory disorders |
| 12/26/2007 | EP1680121A4 Methods and reagents for the treatment of immunoinflammatory disorders |
| 12/26/2007 | EP1524968B1 Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility |